RTP Mobile Logo
Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Colorectal and Gastroesophageal Cancers (Webinar Audio Proceedings)
Released February 2021

Proceedings from a webinar featuring key clinical presentations and papers in colorectal and gastroesophageal cancers. Featuring perspectives from Drs Peter C Enzinger and Zev Wainberg. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal and gastroesophageal cancers.

    LEARNING OBJECTIVES

    • Develop a long-term care plan for individuals diagnosed with metastatic colorectal cancer (mCRC), considering biomarker profile (MSI, HER2), tumor location, prior systemic therapy, symptomatology, performance status and personal goals of treatment.
    • Evaluate available data with anti-PD-1 and anti-CTLA-4 antibodies for microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) mCRC, and appropriately integrate these agents into personalized care plans for patients.
    • Describe ongoing research to validate the potential benefit of immune checkpoint inhibitors in combination with chemotherapy, targeted therapy or other immunotherapies for patients with MSI-H/dMMR or microsatellite-stable mCRC, and use this information to guide trial design and patient referral.
    • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to individualize the selection and sequence of systemic therapy for locally advanced or metastatic gastric or gastroesophageal cancer.
    • Describe the published research data with and ongoing evaluation of immune checkpoint inhibitors in the management of gastric, gastroesophageal junction and esophageal cancers, and identify patients who may be eligible for this strategy as part of a clinical research study or outside of a protocol setting.
    • Recall the biologic rationale for and available data with the use of trastuzumab deruxtecan for patients with previously treated HER2-positive CRC or gastric/gastroesophageal cancer, and discern the current and potential clinical applicability of this strategy.
    • Devise a rational approach to the incorporation of TAS-102 into the treatment algorithms for previously treated locally advanced or metastatic CRC or gastric/gastroesophageal cancer.
    • Identify ongoing clinical trials evaluating novel agents and strategies for CRC and gastroesophageal cancer, and counsel appropriate patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/YIRCRCGastric21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/YIRCRCGastric21/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/YIRCRCGastric21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/YIRCRCGastric21.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Peter C Enzinger, MD
    Director, Center for Esophageal and Gastric Cancer
    Dana-Farber/Brigham and Women’s Cancer Center
    Institute Physician, Dana-Farber Cancer Institute
    Associate Professor, Harvard Medical School
    Boston, Massachusetts

    Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Taiho Oncology Inc, Takeda Oncology, Zymeworks.

    Zev Wainberg, MD, MSc
    Co-Director, GI Oncology Program
    Director of Early Phase Clinical Research
    Jonsson Comprehensive Cancer Center
    UCLA School of Medicine
    Los Angeles, California

    Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Molecular Templates; Contracted Research: Arcus Biosciences, Five Prime Therapeutics Inc, Novartis, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Sumitomo Dainippon Pharma Oncology Inc and Taiho Oncology Inc.

    Release date: February 2021
    Expiration date: February 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):